Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of UI15AML055MT vs Amosartan in Healthy Volunteers
NCT02166398Phase 1Completed
- Sponsor
- Korea United Pharm Inc.
- Start
- Jun 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of UI15AML055MT in hypertension (HTN) (2 arms), sponsored by Korea United Pharm Inc. Primary endpoints: Area Under the Curve (AUClast and AUCinf) of Amlodipine at 144 hours, Maximum Plasma Concentration (Cmax) of Amlodipine at 144 hours and 2 more. Started Jun 2014; status: completed.
02
Drugs
UI15AML055MT
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02166398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02166398.